secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0000950170-24-061087
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Breakthrough Therapy designation to Nuvalent's NVL-655 for ALK+ NSCLC
--------------------------------------------------------------------------------

- NVL-655 received FDA Breakthrough Therapy designation for ALK-positive non-small cell lung cancer.
- Designation covers patients with locally advanced or metastatic disease after two or more prior ALK TKIs.
- Breakthrough Therapy status may accelerate development and FDA review for serious conditions.
- Announcement date: May 16, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024061087/0000950170-24-061087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024061087/nuvl-20240516.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-061087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer